BioAdaptives Moves into Psychedelic Drug Development with Proposed Xycota Acquisition
US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company ...
US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company ...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT ...
The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...
US biotechnology company Enveric Biosciences has reported encouraging laboratory results for EB-003, an experimental psychiatric medicine designed to promote neuroplasticity ...
The Nasdaq-listed psychedelic medicine developer is expanding its workforce, preparing a US sales operation and engaging healthcare providers ahead of ...
Entropy Neurodynamics, GH Research and Helus Pharma are taking different approaches to a shared challenge: developing psychedelic medicines that can ...
The next phase of psychedelic drug development may not involve psychedelics in the traditional sense. As researchers and pharmaceutical companies ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
